Experimental drug shows promise in Huntington’s

A metal protein-attenuating compound may improve cognitive performance in patients with Huntington’s disease, according to research carried out at US and Australian centres.

Published in the Lancet Neurology, the phase 2 study randomised 109 people with early- to mid-stage Huntington’s to six months of the drug PBT2 (250mg or 100mg daily) or to placebo.

The drug was well tolerated and found to be safe,